SOTIO Biotech is at the forefront of developing innovative immunotherapies aimed at treating various solid tumors. The company’s pipeline includes a range of internally developed and in-licensed candidates, with a strong emphasis on enhancing the safety and efficacy of these therapies through rigorous clinical development. Among their key technologies are immunocytokines, which are designed to selectively activate immune cells within the tumor microenvironment, and antibody-drug conjugates (ADCs), which combine a targeted antibody with a potent cytotoxic agent to deliver treatment directly to tumor cells. SOTIO's ADC platform addresses common challenges in the field, such as narrow therapeutic windows and unstable linkers, by utilizing advanced conjugation technologies that enhance the stability and efficacy of the drugs.

Additionally, SOTIO is advancing its BOXR cell therapy platform, which aims to improve the functionality of engineered T cells. This platform identifies novel transgenes that can be co-expressed with tumor-targeting receptors, thereby overcoming resistance mechanisms and enhancing T cell performance in solid tumors. The company is also engaged in multiple collaborations to expand its ADC capabilities, leveraging proprietary technologies from partners to develop a diverse range of therapeutic programs. Through these innovative approaches, SOTIO Biotech is committed to translating cutting-edge scientific research into effective cancer treatments that can significantly improve patient outcomes.

Czechia (Czech Republic)

SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a proprietary technology designed to improve on the efficacy of CAR T therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group. 

SOTIO Biotech

Company Details